Protective action of total glucosides of paeony on renal tubulointerstitium and its mechanism in diabetic rats

Chinese Pharmacological Bulletin

Volumn 24, Issue 3, 2008, Pages

  Fang, Fang ^a   Wu, Yong Gui ^a   Dong, Jing ^a   Ren, Ke Jun ^a   Qi, Xiang Ming ^a   Liang, Chao ^a   Zhang, Wei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Osteopontin; Total glucosides of paeony; Tubulointerstitium; smooth muscle actin

Indexed keywords

3 NITROTYROSINE; ALPHA SMOOTH MUSCLE ACTIN; GLUCOSIDE; OSTEOPONTIN; PAEONIA RADIX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; KIDNEY INTERSTITIUM; KIDNEY TUBULE DAMAGE; MORPHOLOGY; NONHUMAN; PERIODIC ACID SCHIFF STAIN; PROTEIN EXPRESSION; RAT; TISSUE SECTION; WESTERN BLOTTING;

EID: 45349097441     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Gilbert R E, Cooper M E. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? [J]. Kidney Int,1999,56(5):1627-37.
2. Kelly D J, Wilkinson-Berka J L, Ricardo S D, et al. Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats[J]. Nephrol Dial Transplant,2002,17(6):985-91.
3. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology[J]. Eur J Clin Invest,2004, 34(12):785-96.
4. Xu S Y, Chen M Z, Wei W, et al. Immunopharmacology and clinic [M]//Zhou J H, Liu G Z, editor. Progress in pharmacology and clinics of Chinese Materia Medica Research, 1st. Beijing; Science and Technology of China Press,1992;49-59.
5. Yuan L, Wu Y G, Hao L, et al. Renoprotective effect of total glucosides of paeony and its mechanism in experimental diabetes[J]. Chin Pharmacol Bull,2007,23(6):421-6.
6. Kelly D L, Chanty A, Gow R M, et al. Protein kinase C inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy[J]. J Am Soc Nephrol,2005,16(6):1654-60.
7. Chow F Y, Nikolic-Paterson D J, Atkins R C, et al. Macrophages in streptozotocin-induced diabetic nephropathy; potential role in the renal fibrosis[J]. Nephrol Dial Transplant,2004,19(12):2987-96.
8. Panzer U, Thaiss F, Zahner G, et al. Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis[J]. Kidney Int,2001,59(5):1762-9.
9. Giachelli C M, Lombardi D, Johnson R J, et al. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo[J]. Am J Pathol,1998,152(2):353-8.
10. Persy V P, Verhulst A, Ysebaert D K, et al. Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice[J]. Kidney Int,2003,63(2):543-53.
11. Zheng Y Q, Wei W. Total glucosides of paeony suppresses adjuvant arthritis in rats and intervenes cytokine-signaling between different types of synoviocytes[J]. Int Immunopharmacol,2005,5(10):1560-73.
12. Wang H, Wei W, Wang N P, et al. Effects of total glucosides of peony on immunological hepatic fibrosis in rats[J]. World J Gastroenterol,2005, 11(14):2124-9.
13. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism[J]. Diabetes,2005,54(6):1615-25.
14. Ceriello A, Mercuri F, Quagliaro L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress[J]. Diabetologia,2001, 44(7):834-8.
15. Xu S, Jiang B, Maitland K A, et al. The thromboxanereceptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice[J]. Diabetes,2006,55(1):110-9.
16. Fan J M, Ng Y Y, Hill P A, et al. Transforming growth factor-beta regulates epithelial-myofibroblast transdifferentiation in vitro [J]. Kidney Int,1999,56(4):1455-67.